Human evidence quality

TB-500 (Thymosin Beta-4 fragment): what the human research shows

Certainty varies by clinical outcome. Each claim below is assessed on its own; open one to see the studies and the reasoning.

Research only · Last assessment published November 8, 2026 · Methodology ev-1

Evidence overview

Research volume and reviewed human evidence are different numbers, kept apart.

Indexed publications

Research snapshot 2026.1.1

Human clinical publications

PubMed records classified as human research

Distinct human studies reviewed

of 1 identified

Randomized controlled studies

among reviewed studies

Studies with reported results

Registered, no results available

Unpublished is not negative

Study results assessed for risk of bias

Outcomes with a certainty assessment

Research volume for TB-500 (Thymosin Beta-4 fragment) · Library profile

Claims evaluated

Claims are things to investigate, never established benefits. Evidence for one outcome doesn’t carry over to another.

Claims evaluated for TB-500 (Thymosin Beta-4 fragment)
Claim being evaluated	Eligible human studies	Certainty by outcome
Supports soft-tissue injury recovery	0	Insufficient information to assessAutomated, not human-reviewedFunction and return to activity(patient-important, 0 studies)
Is safe for human administrationSafety	0	Insufficient information to assessAutomated, not human-reviewedAdverse events, serious adverse events and discontinuations(safety, 0 studies)

Human studies

Each distinct study once, however many papers, abstracts or registrations describe it.

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDOther design · Not reported participants · first reported 2026 · automated, not human-reviewed

Population: Adults with stable atherosclerotic cardiovascular disease and endothelial dysfunction, per the registered conditions; eligibility details are not in the record.

Full study record (PLS-00248)

Why the counts differ

Publications, studies and registrations are different units.

These numbers count different things. The research snapshot 2026.1.1 counts 0 human clinical publications: PubMed records, classified by publication type. Here, each reviewed study is counted once (1 in all), however many reports describe it (0 PubMed records, 1 registration, 0 other reports such as meeting abstracts outside PubMed).

Which source records describe which study
Study	Source record	Role
PLS-00248	NCT07487363 · no results postedTB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD	registry entry

Evidence gaps

Research activity gap: No gap identified
Little indexed research of any kind.
Human research gap: Gap identified
Laboratory or animal research exists, but little human research.
Evidence quality gap: Gap identified
Human research exists, but no assessed outcome reaches moderate or high certainty.
Clinical relevance gap: Gap identified
Studies exist but none directly address a claim being evaluated.
Safety evidence gap: Gap identified
Safety is not established with moderate or high certainty for the populations, routes or durations studied.

Timeline

Registrations, publications, posted results and every change to the assessments.

2026-03-23
Registered: NCT07487363
2026-11-08
Claim assessment published (version 1)
2026-11-08
Claim assessment published (version 1)
2026-11-08
Certainty assessment published (version 1)
2026-11-08
Certainty assessment published (version 1)
2026-11-08
Study record published (version 1)

Sources and method

Every assessment links its sources and keeps its full version history. Methodology · All assessments (CSV) · All study records (CSV)

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).